LEXAPRO (escitalopram oxalate) by Forest Devices is escitalopram, the s-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). Approved for anxiety. First approved in 2002.
Drug data last refreshed 20h ago
escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
Lexapro®'s Efficacy After Dose Escalation in Remission Study
Aripiprazole and Lexapro Drug Interaction Study
Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro
Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)
Worked on LEXAPRO at Forest Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.